Testing a new antibody to prevent strep throat in healthy adults
Treatments studied
Part of Ear, nose & throat, Infections, Lungs & breathing, Mouth & dental clinical trials.
This study tests whether a new antibody treatment can safely stop strep throat infections. Healthy adults aged 18-40 will receive the antibody and then be exposed to the strep bacteria in a controlled setting to see if it protects them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 40 years old
- You must be in good overall health with no major medical conditions
- You must not have had your tonsils, adenoids, or spleen removed
- You must not be allergic to more than two antibiotics (like penicillin or azithromycin)
- You must agree to avoid mouthwash for a week after discharge
- You must be willing to stay in the hospital for part of the study and attend follow-up visits over about 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at children ages 5–15 who test positive for Group A strep (often called strep throat). It may help by testing an antibiotic approach with beta-lactam medicines for children who are expected to need treatment.
This study tests a new vaccine designed to protect against Group A Strep bacteria. It will check how safe the vaccine is and how well it boosts your immune system. Healthy young adults between 18 and 25 years old may be eligible.
This study tests a new vaccine called StreptInCor that may help prevent rheumatic fever (a condition caused by strep infections that can damage the heart). It is an early trial to check if the vaccine is safe and produces a good immune response in healthy adults.
This study tests a new vaccine called VAX-A1 in healthy people aged 18–40 to see if it's safe and if it helps the body build protection against Group A Streptococcus (a bacteria that can cause serious infections). You'll receive two vaccine doses and have blood tests and heart monitoring over 6 months.
This study tests a new investigational medicine in healthy adults to see how safe it is and how the body processes it. It is a first-in-human trial, so it is looking for volunteers who are generally well and have normal immune function.
This early-phase trial tests a new antibody-based therapy called SCTB10 in healthy volunteers to see if it's safe and how the body processes it. Participation can help determine the right dose for future patients.
Hear when a new Streptococcal Pharyngitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.